Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value ...

Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...

The Federal Trade Commission (FTC) is taking a closer look at Boston Scientific’s $3.7 billion proposal to acquire neuromodulation developer Axonics, a move that could push back the closing of the ...

Boston Scientific Corporation (“Boston Scientific”) announced on January 8 that it has entered into a definitive agreement to acquire Axonics, Inc. (“Axonics”) for an equity value of approximately ...

Raymond Cohen had a vision about 10 years ago that neurostimulation would be a big part of medical therapy. He was proven right earlier this month when it was announced that the company he started, ...

Medical device maker Boston Scientific said on Monday it had agreed to buy Axonics for $3.7 billion, gaining access to devices used to improve bladder function. The deal marks Boston Scientific's ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20 ® ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along ...

Positioned as one of two companies in an underserved healthcare segment with recession-resistant demand for its services and a better product than the legacy monopolist. Strong historical revenue ...

Ladies and gentlemen, thank you for standing by. Welcome to the Axonics Third Quarter 2023 Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.